KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- Drug Take Back Day at Community Pharmacies is Important Public Health Service April 3, 2025A majority of donors said that environmental concerns were an extremely important reason to practice safe medication disposal.
- The Pharmacist’s Role in Counseling Patients on GLP-1 Medications April 3, 2025With expertise in the management and treatment of diabetes, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, shared her insights on counseling patients using GLP-1 medications.
- Pharmacists Discuss Their Hopes for the Future of Pharmacy in 2025 | APhA 2025 April 3, 2025Experts discuss the evolving landscape of pharmacy through technological advancements, professional development, and advocacy.
- Pneumococcal Disease Concerns Remain Despite Successful Vaccine Introduction April 3, 2025Researchers wanted to understand the distribution of pneumococcal conjugate vaccine serotypes and how they have potential to impact pneumococcal disease severity and burden.
- Shingles Vaccination May Lead to Reduction in Dementia Diagnoses April 3, 2025Previous research shows herpes zoster is associated with a higher long-term risk of subjective cognitive decline, with increased risk for men who carried APOE ε4.
- Q&A: Education, Accessibility Is Key for Reproductive Health Care | APhA 2025 April 3, 2025As over-the-counter birth control becomes increasingly available, pharmacists are uniquely positioned to bridge critical gaps in reproductive health care.
- FDA Approves Generic Liraglutide for Type 2 Diabetes April 3, 2025As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.
- Bird Flu Hospitalizes 2 More Patients as Outbreaks Increase April 3, 2025Bird flu cases total 70 US patients as more animals are infected.
- Q&A: Topical Analgesics Are Often Underutilized in Pain Management | APhA 2025 April 3, 2025Traditional approaches have typically relied on oral medications, which can expose the entire body to potentially harmful adverse effects.
- Pregnancy Could Help Reduce the Risk of Long COVID April 2, 2025A study found that patients who acquired a SARS-CoV-2 infection during pregnancy had a lower risk of developing long COVID compared to those who were not pregnant.
Pharmacy Times articles
- FDA Approves Inebilizumab to Treat Adult Patients With IgG4-RD April 3, 2025This action makes inebilizumab the first and only FDA-approved treatment for adults with immunoglobulin G4-related disease (IgG4-RD).
- Low HDL-C, Triglyceride Levels in Late Life Independently Associated With Alzheimer Disease and Related Dementias April 3, 2025Notably, high levels of high-density lipoprotein cholesterol (HDL-C) were not associated with the risk of dementia following adjustments for triglyceride levels.
- Study: Prevalence of Micronutrient Deficiencies in Patients With Type 2 Diabetes April 3, 2025Pharmacists can address micronutrient deficiencies, aiding those with type 2 diabetes as they face a higher risk.
- Siremadlin Demonstrates Efficacy, Safety in Treatment of Patients With TP53 Wild-Type Chronic Lymphocytic Leukemia April 3, 2025Siremadlin is a novel, investigational, second-generation antagonist that binds to MDM2.
- Organon Expands Portfolio With Biosimilar Tocilizumab-bavi for Arthritis and COVID-19 April 3, 2025Tocilizumab-bavi received FDA approval in September 2023 as the first biosimilar to tocilizumab for the treatment of various adult and pediatric arthritis conditions.
- FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis April 3, 2025No manufacturing or safety issues were identified, but the FDA stated the new drug application did not demonstrate efficacy in adequate and well-controlled studies.
- The Landscape of Drug Development and the Pharmaceutical Industry in Italy: Challenges, Trends, and the Role of Generics April 3, 2025Generics play a crucial role in mitigating drug shortages by offering a real alternative for 80% of drugs that are becoming increasingly unavailable in Italy.
- Integrated Multi-Omic Data: Powering Precision Medicine April 3, 2025Through increased utilization of multi-omic data, health care professionals can revolutionize the treatment paradigm of countless diseases.
- Researchers Use CRISPR Screens to Identify Factors Influencing Trastuzumab Emtansine Sensitivity, Resistance April 3, 2025The predictive tool may reveal the mechanisms underlying treatment resistance in patients with HER+ breast cancer.
- FDA Grants Accelerated Approval to Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy April 3, 2025Positive results from an interim analysis of the phase 3 ALIGN study bolstered atrasentan towards receiving accelerated approval for patients with immunoglobulin A nephropathy, a rare condition that can cause kidney failure.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com